Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05371795
Other study ID # CONFORTATTOO
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 18, 2021
Est. completion date September 2022

Study information

Verified date June 2022
Source Instituto Portugues de Oncologia, Francisco Gentil, Porto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparison on radiotherapy skin set-up markings with lancets versus Comfort Marker 2.0®


Description:

A Prospective, unicentric, randomized, controlled, parallel, double-blinded, cohort study comparing radiotherapy skin set-up markings with lancets versus electric marking device (Comfort Marker 2.0® by CIVCO®)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date September 2022
Est. primary completion date March 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age at least 18 years old. - Patients referred to our department to receive external beam radiation therapy. - Eastern Cooperative Oncology Group performance status of 0 to 1. - Estimated fractionating schedule of at least 13 once-daily fractions. - Written informed consent. Exclusion Criteria: - Patients requiring either immobilisation thermoplastic masks (for head or head and shoulders) or vacuum cushion.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Comfort Marker 2.0
The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
Lancets
The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.

Locations

Country Name City State
Portugal Instituto Português de Oncologia do Porto Francisco Genti Porto

Sponsors (1)

Lead Sponsor Collaborator
Instituto Portugues de Oncologia, Francisco Gentil, Porto

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Other Tattoo fading A photographic assessment is performed. Every set-up marking is individually photographed a. All photographs are scored by indepe6 months after completion of the RT. All photographs are scored by independent observers(both physicians and RTTs) blind to patient identity and treatment allocation, on a five-point scale (corresponding from bad to excellent fading). 6 months from the end of irradiation
Primary Patients' comfort Comfort is verbally assessed on the 11-point numeric pain scale. As more than one reference point is tattooed, the patients are asked to give an overall score to the procedure. Day 1
Primary Effectiveness Effectiveness is assessed by the RTT team that delivered the daily fractions. Skin markings are individually evaluated at several periods, specifically at the first fraction, then every 5 fractions, and one last time in the last fraction of RT. These evaluations are scored on a 4-point graded scale (corresponding to bad, reasonable, good, and excellent). up to 7 weeks
Secondary RTTs' satisfaction The RTT that executed the tattooing is asked to score the ease of the process on a three-point scale (easy, medium, and hard). Day 1
Secondary Cosmesis A photographic assessment is performed. Every set-up marking is individually photographed on one of the last three days of treatment. All photographs are scored by independent observers (both physicians and RTTs) blind to patient identity and treatment allocation, on a five-point scale (corresponding from bad to excellent cosmesis). one of the last three days of irradiation
See also
  Status Clinical Trial Phase
Recruiting NCT03212742 - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Phase 1/Phase 2
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Withdrawn NCT02542137 - Abscopal Effect for Metastatic Small Cell Lung Cancer Phase 2
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01168479 - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer Phase 3
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Completed NCT03280719 - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT05514327 - A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL N/A
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Recruiting NCT03370926 - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Active, not recruiting NCT02428049 - Radiation Pneumonitis After SBRT for NSCLC
Recruiting NCT04923620 - Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Recruiting NCT03210428 - Quantitative MR Imaging in Locally Advanced Cervical Cancer
Recruiting NCT05364411 - HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC N/A